Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland. It is one of the largest pharmaceutical companies by both market capitalization and sales.

Wikipedia
Novartis
Novartis
Blog Post
  • When Donald Ganem, MD, joined the NIBR team as head of the Infectious Disease (ID) group in January 2011, he made what he calls a natural step in a career always focused at the intersection of research and clinical medicine.“Those who know me very well could have predicted that I would make this move to come to NIBR,” says Ganem who had been on faculty at the University of California, San Francisc...

Novartis
Novartis
Blog Post
  • But what if they didn’t need as much tissue to complete their work? Could the needle size shrink?Enter 3-D printing, which has been making international headlines over the past couple of years, showcasing the technology’s ability to quickly and inexpensively create everything from prosthetic body parts to clothing and art. It’s also transforming research in the lab, enabling scientists to reinvent...

Novartis
Novartis
Blog Post
  • Forty years later, Cambodian-born Sokhom Pin still has nightmares about what he endured as a child. In one recurring dream, he visits Cambodia, and, once again, the Khmer Rouge has taken over and is shooting people in the streets. Pin runs around all night, desperately searching for the US embassy. Then he wakes up in a sweat . . . in a comfortable house in Lunenburg, MA, with his wife and childre...

Novartis
Novartis
Blog Post
  • Sub-Saharan Africa is facing a healthcare tipping point. Policy and resources are mainly dedicated to fighting infectious diseases today. HIV, malaria and tuberculosis are the big targets. But over the next 15 years chronic diseases like cancer, heart disease, and kidney failure will become the major killers. By 2030 they will account for 42% of all deaths in the region, up from 25% today, says th...

Novartis
Novartis
Blog Post
  • Heart failure is the biggest single cause of hospital admissions in adults aged over 65 in the Western world. It affects 26m people worldwide and more than 1 million new cases are diagnosed every year.More people die from heart failure than from some advanced cancers, including breast and bowel cancer. Ageing populations and deteriorating lifestyles mean heart failure is the most rapidly growing c...

Novartis
Novartis
Blog Post
  • Spinal muscular atrophy (SMA) offers challenges both exciting and daunting to biomedical researchers: Exciting because of its well understood genetics and daunting because no one has yet succeeded in delivering an approved therapy for patients with the devastating neurodegenerative disease.Novartis researchers are hopeful that their efforts to develop SMA treatments that target the underlying mech...

Novartis
Novartis
Blog Post
  • Launching drug discovery for a rare disease takes guts. Not only do researchers make bold bets on new science, they often need to join forces with collaborators and push themselves beyond their comfort zones.Novartis scientists have collaborated widely in a discovery project for spinal muscular atrophy (SMA), a devastating rare disease and the most common genetic cause of infant and toddler fatali...

Novartis
Novartis
Blog Post
  • All 21 patients left the facility with no trace of the disease, a finding reported in the New England Journal of Medicine. That might not sound unusual — several malaria treatments are available — but as the first signs of drug resistance are being seen in Southeast Asia, this trial—while preliminary—showed real promise for novel treatments.The drug candidate tested during this trial, KAE609, migh...

Novartis
Novartis
Blog Post
  • In a medical treatment facility on the Thai-Burmese border, 21 patients infected with malaria recently participated in a clinical trial. All 21 patients left the facility with no trace of the disease, a finding reported in the July 31 issue of the New England Journal of Medicine. That might not sound unusual — several malaria treatments are available — but as the first signs of drug resistance are...

Novartis
Novartis
Blog Post
  • The discovery suggests a new therapeutic strategy for the neurodegenerative disease.Outbreaks of mad cow disease in the 1980s and 1990s highlighted a seemingly rare biological phenomenon: abnormal proteins behaving like infectious agents. The bovine brains contained prions, misfolded versions of normal proteins that spread from neuron to neuron, slowly degrading the cells they inhabit. Until recen...

Novartis
Novartis
Blog Post
  • On a sweltering summer day in 2013, wrapped in ceremonial blue, gold, and red kimonos, Tomi Miagi smiles as the crowd packed into the Shioya district’s tiny town hall erupts in thunderous applause. Tomi had recently turned 97 and in Ogimi village on the Japanese island of Okinawa, this is cause for a special celebration.The seaside town is famous for the longevity of its citizens, with the highest...

Novartis
Novartis
Blog Post
  • The oncology world experienced a revolution about 10 years ago as the first targeted therapies came on the scene. Researchers feverishly designed treatments that would spare healthy tissue, tackling the specific molecular defects of cancer cells. But soon a problem cropped up: tumors began to resist the new drugs.As tumors adapted, so did scientists. They resolved to combine targeted therapeutic a...

Novartis
Novartis
Blog Post
  • LEE011 is a small-molecule inhibitor of two proteins—cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6), components of a switch that controls the cell cycle. The switch is frequently stuck in the “on” position in cancer cells, leading to uncontrolled growth. A variety of molecular signaling pathways—including RAS, RAF, MEK, ERK, PI3K, AKT and mTOR—converge on the switch, and cha...

Novartis
Novartis
Blog Post
  • LJM716 is an antibody designed to inhibit a protein called HER3, which has been implicated in resistance to multiple targeted agents. In fact, it’s emerging as a common release valve for cells under therapeutic pressure, especially in tumors treated with a particular class of inhibitors (PI3K inhibitors).The promise of LJM716 lies in its combination with other targeted agents.Alex Morozov, Oncolog...

Novartis
Novartis
Blog Post
  • ABL001 is a small molecule designed to inhibit BCR-ABL, the same protein hit by imatinib and nilotinib, which are used to treat chronic myelogenous leukemia. But ABL001 has a different mechanism of action. It doesn’t bind the active site of its target. Instead it binds a different region of BCR-ABL, forcing a conformational change that disables the protein’s active site. According to preclinical m...

Novartis
Novartis
Blog Post
  • Imagine having a mobile device that monitors your health so thoroughly that your personal health information will be sent to your physician or care team, enabling them to call you to discuss your symptoms and treatment options in real-time.This scenario is no longer science fiction. Healthcare and technology companies are developing increasingly sophisticated mobile health applications, services a...

Novartis
Novartis
Blog Post
  • “Our goal is to empower people with type 2 diabetes and physicians to effectively manage the disease and our guidance is unique, in that it encourages partnership between the two groups,” said Sir Michael Hirst, an author of the white paper published in Diabetes Research and Clinical Practice and President of the International Diabetes Federation. “While diabetes is a devastating disease, it can b...

Novartis
Novartis
Blog Post
  • When he was a young teen, the close uncle who was raising him died after suffering through a protracted lung illness. Katundu questioned the variety of prescribed and traditional herbal medicines he watched his uncle take during his final days. Few of the medicines seemed to provide any noticeable benefit. Katundu wondered if there was anything he could do to change that for someone else in the fu...

Novartis
Novartis
Blog Post
  • Failure didn’t stop Dr. Richard Roberts. The Nobel laureate failed high-school physics before excelling at the subject and rising to scientific stardom as a genetics and molecular biology pioneer. Co-winner of the 1993 Nobel Prize in Physiology and Medicine for the discovery of split genes, Dr. Roberts shared his story with local middle and high school students gathered at Novartis Institutes for ...

Novartis
Novartis
Blog Post
  • That’s because scientists are currently working to develop a number of treatments that are expected to be more effective than traditional chemotherapies in stopping cancer, and may also ultimately be shown to have fewer side effects. They’re also finding that combinations of these targeted therapies have the potential to be even more effective in slowing or even halting cancer growth.These biologi...

Novartis
Novartis
Blog Post
  • On January 9, 2007, Steve Jobs launched a revolution when he pulled an unfamiliar device out of his pocket and told a room of 5,000 tech-geeks that his company was “going to reinvent the phone.” The device could do unimaginable things, he said, like search the web, make calls, and play music all with a remarkably simple user-interface. At the time it did not seem possible, now it’s hard to imagine...

Novartis
Novartis
Blog Post
  • Imagine a system that cools your house down in summer, then stores the extracted heat and uses it to keep you warm in winter. It sounds too good to be true, but that is exactly what will happen in three buildings under construction at the global headquarters of Novartis – thanks to an environmentally-friendly scheme to store heat in the bedrock deep underground.The principle, known as thermal ener...

Novartis
Novartis
Blog Post
  • What is Power of One? What difference will it make for children in Africa?Edlund: Power of One is a campaign by Malaria No More, its partners – including Novartis – and the public to end malaria deaths, one dollar and one child at a time. Malaria kills a child every minute, but Power of One lets you stop the clock by donating one dollar to provide a malaria test and treatment for a child in Africa...

Novartis
Novartis
Blog Post
  • One in five people in Europe will experience heart failure, a life threatening disease where the heart is unable to pump enough blood around the body, but fewer than one in three adults over the age of 50 are aware of this risk, according to a recent survey.To understand the general population’s awareness of heart failure, Novartis conducted Europe’s largest ever heart failure awareness survey tha...

Novartis
Novartis
Blog Post
  • When research scientist Elaine Donohue arrives at the Novartis Screening Group each morning, anyone tagging along with her could be forgiven for thinking they’d just stepped onto the set of a sci-fi movie. That’s because Donohue works with robots – many of them. And relations between the scientists and the robots are so close that the scientists have named all the robots after candy bars.That bit ...

Novartis
Novartis
Blog Post
  • Ahead of World Malaria Day on April 25, 2 million pediatric antimalarials from Novartis arrived in Zambia as part of Malaria No More's Power of One campaign. The initial delivery included 1 million treatments donated by Novartis, matching 1 million treatments funded with public donations. Zambia is the first beneficiary country of the campaign, and Novartis is the exclusive treatment sponsor.Our c...

Novartis
Novartis
Blog Post
  • An important finding published in the journal Cell adds insight to a 30-year mystery about how cells sense their environment, and could translate into help for diseases where water balance and cell volume are key, such as diabetes and stroke.Our cells are constantly in a state of flux, working to maintain equilibrium to keep them alive. For instance, their membranes are permeable to water, which m...

Novartis
Novartis
Blog Post
  • All of them blind or nearly blind, they’ve journeyed by foot, by train and by bus from far-flung Indian villages to Kolkata for a chance to have their eyesight restored aboard Orbis’ legendary Flying Eye Hospital.The eye surgeries and laser treatments they receive while the plane is parked at Kolkata’s bustling international airport will be nothing short of life-changing for them. But the work abo...

Out-Market Your Competitors?

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account Log in

By signing up, you agree to the Terms of Service and Privacy Policy.

Out-Market Your Competitors

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account

Already a user?  Log in

By signing up, you agree to the Terms of Service and Privacy Policy.